Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

25.0%

2 terminated/withdrawn out of 8 trials

Success Rate

75.0%

-11.5% vs industry average

Late-Stage Pipeline

13%

1 trials in Phase 3/4

Results Transparency

67%

4 of 6 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Phase 2

4(50.0%)

Phase 1

3(37.5%)

Phase 3

1(12.5%)

8Total

Phase 2(4)

Phase 1(3)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06510504Phase 3Completed

Efficacy of BNC210 in Acute, As-needed Treatment of Anxiety in Social Anxiety Disorder - 1

Role: lead

NCT05193409Phase 2Completed

A Phase 2 Study of BNC210 for the Acute Treatment of Social Anxiety Disorder

Role: lead

NCT04951076Phase 2Completed

A Phase 2b Study of BNC210 Tablet Formulation in Adults With Post-Traumatic Stress Disorder (PTSD)

Role: lead

NCT02933606Phase 2Completed

Phase II Study of BNC210 in PTSD

Role: lead

NCT01034631Phase 1Completed

BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma

Role: collaborator

NCT03548194Phase 2Completed

A Study of BNC210 in Elderly Patients With Agitation

Role: lead

NCT02726334Phase 1Terminated

A Phase I, Dose Escalation Study of BNC101 in Patients With Metastatic Colorectal Cancer.

Role: lead

NCT01624493Phase 1Withdrawn

BNC105P Combination Study in Partially Platinum Sensitive Ovarian Cancer Patients

Role: collaborator

All 8 trials loaded